title: Young dyspeptic patients: with a test-and-treat policy, are the benefits of decreased symptom severity and oesophago-gastric-duodenoscopy workload sustained?
abstract: OBJECTIVE
  To examine the symptom severity and requirement for oesophago-gastro-duodenoscopy (OGD) in young dyspeptic patients 2 years after serological testing for Helicobacter pylori, and to compare the outcomes of seronegative patients with those of seropositive patients.
  
  
  METHODS
  Long-term follow-up study of 232 participants from our previous trial.
  
  
  METHODS
  Telephone assessment of patients' symptom severity, scored using a previously validated questionnaire; return of patients for OGD determined using local patient administration system (PAS); and review of medical case notes.
  
  
  RESULTS
  Dyspepsia symptom severity of both seronegative and seropositive patients remained reduced compared with initial scores at time of trial recruitment. Symptom severity of seropositive patients was significantly lower than that of seronegative patients (P< 0.001). Seventeen additional patients returned for OGD between six months and two years after the start of the serological study. As 61 of the original 232 study patients returned for OGD within the first six month follow-up period, a total of 78 individuals (34%) had OGD during the two years following the study. Thus, 66% of the original participants avoided OGD.
  
  
  CONCLUSIONS
  This study of non-invasive testing for H. pylori in young dyspeptic patients has demonstrated an improvement in symptom severity and a substantial reduction in OGD workload over a 2-year period.
authors.affiliation: Clinical Effectiveness Unit, Kettering General Hospital NHS Trust, Northants, UK.
authors.forename: P E
authors.initials: PE
authors.lastname: Bowie
authors.forename: R A
authors.initials: RA
authors.lastname: Cox
authors.forename: A R
authors.initials: AR
authors.lastname: Davidson
authors.forename: A
authors.initials: A
authors.lastname: Steel
mesh_terms: D000328:Adult; D000367:Age Factors; D000907:Antibodies, Bacterial / Q000097:blood; D004415:Dyspepsia / Q000175:diagnosis* / Q000382:microbiology; D016145:Endoscopy, Digestive System / Q000706:statistics & numerical data*; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000382:microbiology; D016480:Helicobacter pylori / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D013997:Time Factors; D006113:United Kingdom
chemical_list: D000907:Antibodies, Bacterial